STOCK TITAN

Connect Biopharma Holdings Ltd - CNTB STOCK NEWS

Welcome to our dedicated news page for Connect Biopharma Holdings (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Connect Biopharma Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Connect Biopharma Holdings's position in the market.

Rhea-AI Summary
Connect Biopharma appoints James Huang, a seasoned biotech expert, to its Board of Directors. Huang brings over 30 years of experience in the industry and will play a key role in advancing the company's pipeline of therapies for chronic inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
management
-
Rhea-AI Summary
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced positive topline results from the global Phase 2b trial evaluating rademikibart efficacy and safety in adult patients with moderate-to-severe persistent asthma. The trial met its primary endpoint, showing significant improvement in lung function at Week 12 with both doses of rademikibart. The study demonstrated strong and significant improvement in asthma control, with both doses showing early and sustained improvement through Week 24. The safety results suggest rademikibart was generally well tolerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
clinical trial
-
Rhea-AI Summary
Connect Biopharma Holdings Limited (Nasdaq: CNTB) will present top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe asthma on December 12, 2023, before market open. The Company will host a conference call and webcast presentation at 8:30 a.m. ET to discuss the top-line data, featuring Dr. Edward M. Kerwin, MD, Founder and Senior Medical Director of the Clinical Research Institute, Allergy and Asthma Center and Altitude Clinical Consulting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
clinical trial
Rhea-AI Summary
Connect Biopharma (CNTB) and Simcere Pharmaceutical (PR: Simcere Pharmaceutical Group Ltd.) have entered into an exclusive license and collaboration agreement for the development and commercialization of rademikibart in Greater China. Rademikibart is a human monoclonal antibody against IL-4Rα, a common subunit for IL-4R and IL-13 receptors being developed for the treatment of Th2 driven inflammatory diseases. Connect Biopharma will receive a ¥150 million RMB (US$ 21 million) upfront payment, up to ¥875 million RMB (US$ 120 million) upon achieving certain development and commercial milestones, in addition to royalties up to low double-digit percentages of net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.83%
Tags
none
-
Rhea-AI Summary
Connect Biopharma Holdings Limited (CNTB) announced positive topline results from the Stage 2 of its China pivotal trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD). Rademikibart continued to be well tolerated over 52 weeks of treatment, with approximately 90% of patients on Q4W dose maintaining both IGA 0/1 and EASI-75 through Week 52.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.83%
Tags
none
-
Rhea-AI Summary
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announces topline results from the Stage 2 of its China pivotal trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe atopic dermatitis. The company will host a conference call and webcast presentation to discuss the trial results on Tuesday, November 21, 2023, at 8:30 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.83%
Tags
none
Rhea-AI Summary
Connect Biopharma reports financial results and provides business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
earnings
-
Rhea-AI Summary
Connect Biopharma Holdings received a letter from Nasdaq indicating that its bid price for ADSs had closed below the minimum $1.00 per share requirement for continued listing. The company has until March 11, 2024, to regain compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
Rhea-AI Summary
Connect Biopharma to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
Connect Biopharma Holdings Ltd

Nasdaq:CNTB

CNTB Rankings

CNTB Stock Data

64.98M
12.96M
41.29%
44.03%
0.23%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
San Diego

About CNTB

suzhou connect biopharmaceuticals, ltd. is a pharmaceuticals company based out of 10th floor, xiangtang development building, #3 chaoyang dong rd, taicang, china.